Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

altRX vs Vytora Health

Two GLP-1 desks, one scoreboard. We put altRX and Vytora Health head-to-head on the published Brief Score — the same six factors, scored the same way.

No. 218 · Grade C

altRX

Visit altRX Full brief →

FDA warning letter, June 2026 — issued to Trinity HealthCare Supply, LLC dba altRx. See the FDA's warning letter database.

vs
Higher Brief ScoreNo. 16 · Grade B+

Vytora Health

Visit Vytora Health Full brief →

The verdict

Vytora Health takes this head-to-head.

Vytora Health scores 87 to 65 on our six-factor Brief Score — A rare accredited desk that pairs brand-name access with fair mid-market compounded pricing across all 50 states.

That doesn't make altRX a bad call — it's best for readers who want the only platform offering all four brand-name glp-1s plus compounded. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
48
85
Supply Reliability
81
87
Transparency
72
88
Access Breadth
56
90
Clinical Oversight
82
88
Track Record
51
82
altRXBrief Score 65 · 87Vytora Health

Price, coverage & the tracker

altRXVytora Health
Brief Score65/100 (C)87/100 (B+)
SemaglutideFrom $149/mo (starting dose, compounded)$150/mo
TirzepatideFrom $249/mo (starting dose, compounded)$200/mo
CoverageCoverage not publishedAll 50 states
Brand-name accessYesYes
Oral / sublingualInjection onlyInjection only
On the trackerNewnew to the tracker, no prior readingStableprice stable

altRX: New to the tracker on 1 August 2026. The published line reads From $149/mo (starting dose, compounded) at our first reading; there is no earlier reading of ours to compare it against yet.

Vytora Health: $150 sema / $200 tirz nationwide; LegitScript-certified with brand-name access.

Not sold on either?

CoreAge Rx tops the whole ranking at 94/100.

The steadiest desk in the ranking: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.